“…Based on these observations, we inquired whether oxazolone is representative of a broader class of environmental factors that may be involved in the pathogenesis of IBD and possess a conserved or shared substructure. Oxazolone, first synthesized in 1883 by Erlenmeyer and Plöchl (Plöchl, 1884; Erlenmeyer, 1893), has been widely utilized as a synthetic building block for compounds with a range of pharmacological properties (Turchi, 2008) and is also naturally abundant in diet as a component of many thermally processed foods, pesticides, and other environmental sources (Maga, 1978). In addition, microbes are another abundant source of oxazoles as part of a structurally functionally diverse class of ribosomally derived peptides, dubbed TOMMs, that are widely disseminated across the phylogenetic spectra of bacterial secretion systems, including potential pathobionts associated with IBD pathogenesis or skin inflammation (Mazmanian et al, 2008; Melby et al, 2011).…”